Dr. Andreas Vogt

• Dr. Andreas Vogt, Research Assistant Professor, Department of

Pharmacology; and Associate

Director, Fiske Drug Discovery Laboratory, University of Pittsburgh School of Medicine

Andreas Vogt, Ph.D., Assistant Professor, Pharmacology, University of

Andreas Vogt, research assistant professor of pharmacology in Pitt's School of Medicine, will focus on high throughput screening, exploiting Pitt's existing expertise in screening compounds in the context of whole cells.

Andreas Vogt, Michael G. Tarpley, Kathleen A. Cooley, Peter Wipf, and John S. Lazo University of Pittsburgh
...
Presenting author: Andreas Vogt, University of Pittsburgh, USA

Few cell-active inhibitors of the oncogenic cell-cycle phosphatase Cdc25 have been described.To assess the utility of a cell-based assay as a primary drug discovery screen, we have evaluated 1991 compounds in the NCI DiverSet for phospho-Erk accumulation in intact cells.The assay yielded an initial hit rate of 1.7% (34 compounds).Ten of these (0.5%) were confirmed by microscopic examination.Of the 10 verified hits, six (60%) inhibited Cdc25B in vitro by more than 50%.Four compounds inhibited Cdc25B by over 80%, and none inhibited VHR or PTP1B.A focused library with submicromolar in vitro Cdc25 inhibitory activity containing 22 agents from the NCI repository and 14 synthetic analogs showed a substantial enrichment for phospho-Erk accumulators (7 out of 36 or 19.5%) compared with the parent NCI library.

Pitt's center was selected because of the unique expertise of its investigators, including Dr. Lazo, who will direct a core devoted to assay implementation; Andreas Vogt, Ph.D., research assistant professor of pharmacology in Pitt's School of Medicine, will focus on high throughput screening, which will exploit Pitt's existing expertise in screening compounds in the context of whole cells.

• Dr. Andreas Vogt, Research Assistant Professor, Department of Pharmacology; and AssociateDirector, Fiske Drug Discovery Laboratory, University of Pittsburgh School of Medicine

Dr. Andreas Vogt, Research Assistant Professor, Pharmacology, University of Pittsburgh

Assistants: Dana Cupkova, Todd Rouhe, Katrin Kloetzer, Andreas Vogt, Andreas Quednau

"We are hoping to have the drug in clinical trials maybe by the end of next year", said Andreas Vogt, PROLX's scientific director and a part-time professor in the University of Pittsburgh's department of Pharmacology.